Introduction to Highly Anticipated Data From The Solo 1 Trial
Exploring Highly Anticipated Data From The Solo 1 Trial reveals several interesting facts. Medical oncologists assess the
Highly Anticipated Data From The Solo 1 Trial Comprehensive Overview
Olaparib may be beneficial for patients with advanced, BRCA-mutated ovarian cancer according to the results of the Dr Kathleen Moore presented Press Briefing 2, October 20 - Ovarian Cancer: LBA7_PR - Maintenance olaparib following platinum-based chemotherapy in ...
SOLO
Summary & Highlights for Highly Anticipated Data From The Solo 1 Trial
- Maurie Markman, MD, discusses 7-year follow-up results of the
- Dr Moore speaks with ecancer at ESMO 2018 in Munich about results from the
- In this video, Kathleen Moore, MD, principle investigator, from the Stephenson Cancer Center, Oklahoma City, OK, talks about the ...
- Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, presents 7-year overall survival results from the Phase III ...
- An overview of the
Stay tuned for more updates related to Highly Anticipated Data From The Solo 1 Trial.